Cargando…

Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions

Nafamostat mesylate is a serine protease inhibitor used in the treatment of acute pancreatitis. The impurities in nafamostat mesylate, the active pharmaceutical ingredient (API), were profiled via high performance liquid chromatography tandem ion trap coupled with time-of-flight mass spectrometer (H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yuxin, An, Lufan, Zhang, Lin, Wang, Rulin, Tian, Yuan, Zhang, Zunjian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Xi'an Jiaotong University 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474109/ https://www.ncbi.nlm.nih.gov/pubmed/32923008 http://dx.doi.org/10.1016/j.jpha.2020.03.002

Ejemplares similares

Stability profiling of anti-malarial drug piperaquine phosphate and impurities by HPLC-UV, TOF-MS, ESI-MS and NMR
por: Yan, Fang, et al.
Publicado: (2014)

Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
por: Ghali, George Zaki, et al.
Publicado: (2020)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Cardiopulmonary arrest caused by nafamostat mesylate during hemodialysis
por: Shioya, Nobuki, et al.
Publicado: (2022)

Retraction: Nafamostat mesylate attenuates the pathophysiologic sequelae of neurovascular ischemia
Publicado: (2021)

Cytokine expressions of spinal cord injury treated by neurotropin and nafamostat mesylate
por: Sun, Chao, et al.
Publicado: (2021)

Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series
por: Doi, Kent, et al.
Publicado: (2020)

Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients
por: Hifumi, Toru, et al.
Publicado: (2020)

Development of HPLC-CAD method for simultaneous quantification of nine related substances in ursodeoxycholic acid and identification of two unknown impurities by HPLC-Q-TOF-MS
por: Huang, Yiwen, et al.
Publicado: (2023)

Comparison of ESI– and APCI–LC–MS/MS methods: A case study of levonorgestrel in human plasma()
por: Wang, Rulin, et al.
Publicado: (2016)

Simultaneous Determination of 15 Sulfonate Ester Impurities in Phentolamine Mesylate, Amlodipine Besylate, and Tosufloxacin Tosylate by LC-APCI-MS/MS
por: Jin, Bo, et al.
Publicado: (2019)

Dynamic changes in fibrinogen and D-dimer levels in COVID-19 patients on nafamostat mesylate
por: Osawa, Itsuki, et al.
Publicado: (2020)

Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review
por: Hernández-Mitre, María Patricia, et al.
Publicado: (2022)

Application of nafamostat mesylate for anticoagulation in hemoperfusion therapy in patients with bromadiolone poisoning: Case reports
por: Qian, Weiwei, et al.
Publicado: (2023)

Effect of processing on the alkaloids in Aconitum tubers by HPLC-TOF/MS()
por: Liu, Min, et al.
Publicado: (2017)

Separation and determination of acetyl-glutamine enantiomers by HPLC–MS and its application in pharmacokinetic study
por: Zhang, Xiaoxiao, et al.
Publicado: (2017)

Nafamostat mesylate-induced hyperkalemia in critically ill patients with COVID-19: Four case reports
por: Okajima, Masaki, et al.
Publicado: (2020)

Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article
por: Abduljabbar, Maram H.
Publicado: (2021)

Anaphylactic Reactions Caused by Nafamostat Mesylate during Hemodialysis before Surgery for Carpal Tunnel Syndrome
por: Nakamura, Yuta, et al.
Publicado: (2021)

Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach
por: Kim, Hyeon-A, et al.
Publicado: (2022)

Nafamostat mesylate prevents metastasis and dissemination of neuroblastoma through vascular endothelial growth factor inhibition
por: Morimoto, Mari, et al.
Publicado: (2022)

AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study
por: Hirayama, Takahiro, et al.
Publicado: (2017)

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
por: Hoffmann, Markus, et al.
Publicado: (2020)

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
por: Chen, Xi, et al.
Publicado: (2019)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors
por: C, Amrutha M, et al.
Publicado: (2023)

Evaluation of the Effects of Processing Technique on Chemical Components in Raphani Semen by HPLC and UPLC-Q-TOF-MS
por: Gao, Sijia, et al.
Publicado: (2022)

Serum Metabolomics Study of Papillary Thyroid Carcinoma Based on HPLC-Q-TOF-MS/MS
por: Du, Yang, et al.
Publicado: (2021)

Determination of Doxazosin Mesylate in Tablets by RP-HPLC
por: Dhanya, B., et al.
Publicado: (2011)

Nafamostat mesylate, a serine protease inhibitor, demonstrates novel antimicrobial properties and effectiveness in Chlamydia-induced arthritis
por: Inman, Robert D, et al.
Publicado: (2012)

Treatment effect of nafamostat mesylate in patients with COVID-19 pneumonia: study protocol for a randomized controlled trial
por: Moon, Kyunglan, et al.
Publicado: (2021)

Association between Nafamostat Mesylate and In-Hospital Mortality in Patients with Coronavirus Disease 2019: A Multicenter Observational Study
por: Inokuchi, Ryota, et al.
Publicado: (2021)

Correction: Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
por: Kameda, Shinya, et al.
Publicado: (2023)

Quantitative and qualitative analyses of cytotoxic triterpenoids in the rhizomes of Anemone raddeana using HPLC and HPLC-ESI-Q/TOF-MS
por: Zhao, Ying, et al.
Publicado: (2018)

Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltlation with nafamostat mesylate
por: Iwasaka, Sho, et al.
Publicado: (2020)

Nafamostat mesylate overcomes endocrine resistance of breast cancer through epigenetic regulation of CDK4 and CDK6 expression
por: Lin, Yueh-Te, et al.
Publicado: (2021)

Integration of transcriptomics and metabolomics reveals the molecular mechanisms underlying the effect of nafamostat mesylate on rhabdomyolysis-induced acute kidney injury
por: Guo, Wenli, et al.
Publicado: (2022)

Chemical Profiles and Simultaneous Quantification of Aurantii fructus by Use of HPLC-Q-TOF-MS Combined with GC-MS and HPLC Methods
por: He, Yingjie, et al.
Publicado: (2018)

Identification of nafamostat mesylate as a selective stimulator of NK cell IFN-γ production via metabolism-related compound library screening
por: Yang, Qinglan, et al.
Publicado: (2022)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_652h8lrdvauiod225i8mm6gkk7